Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Teva will pay $700 million up front and possibly as much as $200 million more if ecopipam hits certain commercial goals. Teva CEO Richard Francis described the…
Teva Form 8-K (filed Apr 29, 2026; accession 000117184326002796) reporting the definitive agreement to acquire Emalex Biosciences: $700M upfront plus up to…
Teva Pharmaceuticals will pay $700 million upfront with potential commercial milestone payments up to $200 million plus royalties to acquire Emalex Biosciences…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Teva will acquire Emalex Biosciences for $700M cash upfront plus up to $200M commercial milestones and net sales royalties to add NDA-ready ecopipam (first-in-class D1 antagonist) for pediatric Tourette syndrome to its neuroscience pipeline; NDA submission expected 2H 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Emalex Biosciences, Inc. (this deal) | 2026 | $900M | — |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
← Browse all deals · How we score deals
More: 2026 deals · Teva Pharmaceutical Industries Ltd. deals · Neurology deals